HK1048126B - Soluble ctla4 mutant molecules and uses thereof - Google Patents

Soluble ctla4 mutant molecules and uses thereof Download PDF

Info

Publication number
HK1048126B
HK1048126B HK03100239.8A HK03100239A HK1048126B HK 1048126 B HK1048126 B HK 1048126B HK 03100239 A HK03100239 A HK 03100239A HK 1048126 B HK1048126 B HK 1048126B
Authority
HK
Hong Kong
Prior art keywords
ctla4 mutant
ctla4
cell
mutant molecule
molecule
Prior art date
Application number
HK03100239.8A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1048126A1 (en
Inventor
J. Peach Robert
R. Naemura Joseph
S. Linsley Peter
Bajorath Jurgen
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HK1048126A1 publication Critical patent/HK1048126A1/en
Publication of HK1048126B publication Critical patent/HK1048126B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100239.8A 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof HK1048126B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US579927 2000-05-26
US21406500P 2000-06-26 2000-06-26
US214065P 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
HK1048126A1 HK1048126A1 (en) 2003-03-21
HK1048126B true HK1048126B (en) 2005-03-04

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100239.8A HK1048126B (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Country Status (41)

Country Link
EP (3) EP1536234B1 (OSRAM)
JP (1) JP4328525B2 (OSRAM)
KR (2) KR100895134B1 (OSRAM)
CN (2) CN1309735C (OSRAM)
AR (1) AR031699A1 (OSRAM)
AT (1) ATE271066T1 (OSRAM)
AU (2) AU6346601A (OSRAM)
BE (1) BE2011C041I2 (OSRAM)
BR (1) BRPI0111191B8 (OSRAM)
CA (1) CA2409748C (OSRAM)
CY (2) CY2011019I2 (OSRAM)
CZ (1) CZ304451B6 (OSRAM)
DE (2) DE60104282T2 (OSRAM)
DK (1) DK1248802T3 (OSRAM)
EC (1) ECSP024365A (OSRAM)
EE (2) EE05458B1 (OSRAM)
EG (1) EG24459A (OSRAM)
ES (2) ES2571852T3 (OSRAM)
FR (1) FR11C0053I2 (OSRAM)
GE (1) GEP20053658B (OSRAM)
HK (1) HK1048126B (OSRAM)
HU (2) HU228137B1 (OSRAM)
IL (1) IL152315A (OSRAM)
LT (1) LT5133B (OSRAM)
LU (1) LU91902I2 (OSRAM)
LV (1) LV12994B (OSRAM)
MX (1) MXPA02011534A (OSRAM)
MY (1) MY136113A (OSRAM)
NO (2) NO330797B1 (OSRAM)
PE (1) PE20011338A1 (OSRAM)
PL (1) PL206267B1 (OSRAM)
PT (1) PT1248802E (OSRAM)
RU (1) RU2283847C2 (OSRAM)
SI (1) SI1248802T1 (OSRAM)
SK (1) SK288131B6 (OSRAM)
TR (1) TR200402703T4 (OSRAM)
TW (2) TWI319405B (OSRAM)
UA (1) UA87432C2 (OSRAM)
UY (1) UY26723A1 (OSRAM)
WO (1) WO2001092337A2 (OSRAM)
ZA (1) ZA200208944B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PL212205B1 (pl) * 2000-07-03 2012-08-31 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
SI1576182T2 (sl) * 2002-12-23 2020-07-31 Bristol-Myers Squibb Company Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
JP5096369B2 (ja) * 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101378302B1 (ko) 2006-12-20 2014-03-28 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
RU2506275C2 (ru) 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
NO2344540T3 (OSRAM) * 2008-10-02 2018-04-28
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
MX2013009741A (es) 2011-02-23 2014-01-17 Amgen Inc Medio de cultivo celular para exposicion a uvc y metodos relacionados al mismo.
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
JP6228971B2 (ja) 2012-05-11 2017-11-08 メディミューン，エルエルシー Ｃｔｌａ−４バリアント
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
KR20150033703A (ko) * 2012-06-27 2015-04-01 오르반 바이오테크 엘엘씨 당뇨병 치료를 위한 ctla4 융합 단백질
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
BR122020004385B1 (pt) 2014-01-13 2022-10-04 Amgen Inc Método para aumentar o teor de glicoforma de alta manose de uma glicoproteína recombinante e método de produção de uma glicoproteína recombinante
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
PT3926051T (pt) 2014-06-04 2024-06-20 Amgen Inc Métodos de colheita de culturas de células de mamíferos
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
EP4667012A2 (en) 2016-09-19 2025-12-24 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
KR102746223B1 (ko) 2017-04-20 2024-12-27 이제네시스, 인크. 유전자 변형 동물의 생성 방법
CA3077509A1 (en) * 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
US11186625B2 (en) 2019-12-06 2021-11-30 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
MX2022016104A (es) 2020-06-18 2023-02-01 Regeneron Pharma Enfoque de peptidos pesados para medir con precision lisina de extremo c-terminal sin procesar.
CN116601279A (zh) 2020-07-28 2023-08-15 思进股份有限公司 用于生产多肽的方法和系统
US20250040546A1 (en) 2021-12-16 2025-02-06 Bristol-Myers Squibb Company Detergent for viral inactivation
WO2023167855A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ES2123001T5 (es) * 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
PL212205B1 (pl) * 2000-07-03 2012-08-31 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4

Also Published As

Publication number Publication date
HU228137B1 (en) 2012-12-28
AU2001263466C1 (en) 2006-10-26
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
HUP0302201A3 (en) 2010-01-28
EP1536234A3 (en) 2009-06-03
CY2011019I1 (el) 2016-12-14
PL206267B1 (pl) 2010-07-30
PL366231A1 (en) 2005-01-24
ATE271066T1 (de) 2004-07-15
PE20011338A1 (es) 2002-01-13
CY2011019I2 (el) 2016-12-14
NO2011027I2 (OSRAM) 2011-12-15
NO20025656D0 (no) 2002-11-25
ECSP024365A (es) 2003-03-31
NO20025656L (no) 2002-11-25
PT1248802E (pt) 2004-11-30
LV12994B (en) 2003-08-20
ES2571852T3 (es) 2016-05-27
EG24459A (en) 2009-07-16
SI1248802T1 (en) 2005-02-28
AU6346601A (en) 2001-12-11
ES2225549T3 (es) 2005-03-16
GEP20053658B (en) 2005-11-10
ZA200208944B (en) 2004-02-13
CZ304451B6 (cs) 2014-05-14
WO2001092337A2 (en) 2001-12-06
CN1441810A (zh) 2003-09-10
MXPA02011534A (es) 2004-08-12
TWI319405B (en) 2010-01-11
EE200200659A (et) 2004-06-15
EP3029062A1 (en) 2016-06-08
LT5133B (lt) 2004-05-25
TW200906857A (en) 2009-02-16
EP1536234A2 (en) 2005-06-01
EE201100050A (et) 2011-10-17
IL152315A (en) 2010-04-15
NO2011027I1 (no) 2012-01-09
DE60104282D1 (de) 2004-08-19
HK1071931A1 (en) 2005-08-05
TWI314933B (en) 2009-09-21
CY1117625T1 (el) 2017-04-26
DE122011100063I1 (de) 2012-06-14
DE60104282T2 (de) 2005-10-13
HUS1300012I1 (hu) 2016-08-29
AR031699A1 (es) 2003-10-01
EP1248802B9 (en) 2005-05-11
BR0111191A (pt) 2004-07-06
IL152315A0 (en) 2003-05-29
CA2409748C (en) 2008-09-16
EP1248802B1 (en) 2004-07-14
JP4328525B2 (ja) 2009-09-09
BE2011C041I2 (OSRAM) 2020-08-20
CA2409748A1 (en) 2001-12-06
LT2002114A (en) 2003-12-29
NO330797B1 (no) 2011-07-18
HK1048126A1 (en) 2003-03-21
CN1309735C (zh) 2007-04-11
BRPI0111191B1 (pt) 2019-12-31
BRPI0111191B8 (pt) 2021-05-25
TR200402703T4 (tr) 2004-11-22
CZ20023892A3 (cs) 2003-09-17
SK15702002A3 (sk) 2004-01-08
HUP0302201A2 (hu) 2003-10-28
KR20030009502A (ko) 2003-01-29
EE05458B1 (et) 2011-08-15
FR11C0053I2 (fr) 2013-01-11
EE05557B1 (et) 2012-08-15
EP1536234B1 (en) 2016-03-16
EP1248802A2 (en) 2002-10-16
MY136113A (en) 2008-08-29
KR100889887B1 (ko) 2009-03-24
FR11C0053I1 (OSRAM) 2012-01-13
KR100895134B1 (ko) 2009-05-04
JP2004511213A (ja) 2004-04-15
UY26723A1 (es) 2001-12-28
DK1248802T3 (da) 2004-11-15
AU2001263466B2 (en) 2006-04-27
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
CN101255192A (zh) 2008-09-03
RU2283847C2 (ru) 2006-09-20
UA87432C2 (uk) 2009-07-27

Similar Documents

Publication Publication Date Title
US20210115107A1 (en) Methods of treatment using ctla4 molecules
EP1248802B9 (en) Soluble ctla4 mutant molecules and uses thereof
AU2006203199B2 (en) Soluble CTLA4 mutant molecules and uses thereof
HK1225393A1 (en) Soluble ctla4 mutant molecules and uses thereof
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF
HK1071931B (en) Soluble ctla4 mutant molecules and uses thereof
NZ522031A (en) Uses of soluble CTLA4 (cytotoxic T-lymphocyte-associated protein 4) fusion molecules mutated from wild-type CTLA4 to retain the ability to bind CD80 and/or CD86
NZ542231A (en) Soluble CTLA4 mutant fusion molecules and uses thereof

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210522